Navigation Links
Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
Date:4/8/2013

BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting multiple sclerosis (RR-MS). Decision Resources forecasts that Tecfidera will earn a patient share similar to surveyed neurologists' estimate in the U.S. RR-MS market by 2021, owing to its robust efficacy—specifically, a greater reduction in annualized relapse rate (ARR) relative to first-line agents—and a strong safety profile relative to the most effective current therapies, such as Biogen Idec's Tysabri.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase 2013 report entitled Where Do Physicians and Payers Signal the Greatest Need—and Greatest Opportunity—for New Therapeutic Advances? also finds that, according to insights from surveyed U.S. and European neurologists and managed care organizations' (MCO) pharmacy directors, an increased effect in preventing sustained disability progression is one of the greatest unmet needs in RR-MS. Clinical data and the opinions of interviewed thought leaders indicate that Genzyme/Sanofi/Bayer HealthCare's emerging agent Lemtrada has demonstrated the potential to partially fulfill this unmet need.

Surveyed U.S. MCO pharmacy directors are also particularly receptive to new RR-MS therapies that offer a greater reduction in ARR over currently available therapies.

"We expect that several emerging agents, notably Lemtrada and potentially Roche/Genentech's ocrelizumab, will match the improvements on reduction in ARR that surveyed U.S. payers indicated would be required to achieve widespread inclusion and price premiums on MCO formularies," said Decision Resources Analyst John Crowley , Ph.D.

The report also finds that surveyed U.S. and European neurologists agree that reduction in ARR and the risk of serious or life-threatening sides effects are attributes that most influence their prescribing decisions in RR-MS—findings that likely underlie their positive outlook for Tecfidera.

Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec's daclizumab—have advantages in reducing ARR over Teva's Copaxone, the sales-leading agent for treatment of RR-MS. The unique risk/benefit profiles of new therapeutic alternatives will be heavily scrutinized as neurologists incorporate them into the evolving MS treatment algorithm.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
2. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
3. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
4. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
5. Protected Classes Prescription Drug Mandates Would Hike Small Business Costs, Drug Company Profits
6. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
7. Free Webinar Helps Physicians and Pharmacists Learn How to ePrescribe Controlled Substances
8. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
9. BioGenex and Abbott Molecular Conclude Successful Partnership
10. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de enfermedades infecciosas, presentó ... a los miembros de la Kenya Pharmaceutical Association. ... ... Test! (PRNewsFoto/bioLytical Laboratories) ... ) bioLytical fue invitada por la Clinton Health Access Initiative ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
(Date:12/2/2016)... FRANCISCO , Dec. 2, 2016  PipelineRx, a ... telepharmacy, will be offering demonstrations of its SaaS-based ... Society of Health-System Pharmacists 2016 Midyear Clinical Meeting ... Vegas . With nearly 300 hospital clients ... services and technology designed to dramatically improve pharmacy ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel ... CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. ... brings extensive financial and operational leadership experience to Advanced Inc. He began his career ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek ... Dr. Murthy explains how he was inspired to practice medicine at an early age ... is about more than making diagnoses and prescribing medicine,” he states. “It is about ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... from high school and while 84 percent of parents report speaking with their child ... control, pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical ... systems and the first company to offer robotic imaging to veterinary medicine is ... booth # 941 for the American Association of Equine Practitioners 62nd Annual Convention ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 ... to create versatile lower third titles with just a few clicks of the mouse," ... 2 includes 30 lower third animations. Choose from various styles with accented animations, rigid ...
Breaking Medicine News(10 mins):